Table 2.
Cx26/Cx32 expression in clinical samples and their correlation with patients’ clinical outcomes
| Cancer Type | Clinical manifest | Ref. |
|---|---|---|
| Cx26 in primary tumor tissues | ||
| Breast | Cytoplasmic Cx26; associated with lymphatic vessel invasion and poor relapse-free survival | [63] |
| Colorectal | Cytoplasmic Cx26; associated with venous invasion, lung metastasis, and poor disease-free survival | [64] |
| FTC | Cytoplasmic Cx26; associated with lymph node metastasis | [65] |
| PTC | Cytoplasmic Cx26; associated with high incidence of intra-glandular dissemination | [65] |
| ESCC | Cytoplasmic Cx26; associated with lymph node metastasis and poor 5-year survival | [66] |
| Melanoma | Cx26 mRNA; associated with poor survival | [24] |
| Breast | Cx26 mRNA; associated with recurrence | [24] |
| Cx26 in metastatic lesions | ||
| Breast | Cell surface Cx26; increased expression in lymph node metastases; cell surface Cx26 was only found in metastatic lesions | [18] |
| Colorectal | Cytoplasmic Cx26; increased expression in lung metastatic lesions | [64] |
| Cx32 in primary tumor tissues | ||
| HCC | Cx32 mRNA; reversely correlated with histological grade and lymph node metastasis | [78] |
| Cx32 mRNA; associated with low vascular invasion and high overall survival rate | [79] | |
| Cx32 in metastatic lesions | ||
| Breast | Cytoplasmic Cx32; increased expression in metastatic lymph nodes | [70] |
FTC Follicular thyroid cancer, PTC Papillary thyroid cancer, ESCC Esophageal squamous cell carcinoma, NSCLC Non-small cell lung cancer, HCC Hepatocellular carcinoma